These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16021143)

  • 1. Treatment of steroid-resistant nodular scabies with topical pimecrolimus.
    Almeida HL
    J Am Acad Dermatol; 2005 Aug; 53(2):357-8. PubMed ID: 16021143
    [No Abstract]   [Full Text] [Related]  

  • 2. [Topical pimecrolimus and tacrolimus and the risk of cancer].
    Sánchez-Pérez J
    Actas Dermosifiliogr; 2007 Jun; 98(5):312-7. PubMed ID: 17555673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series.
    Lonsdale-Eccles AA; Velangi S
    Br J Dermatol; 2005 Aug; 153(2):390-4. PubMed ID: 16086755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pimecrolimus and tacrolimus: the US FDA public health advisory.
    Maddin S
    Skin Therapy Lett; 2005 May; 10(4):1-3. PubMed ID: 15986080
    [No Abstract]   [Full Text] [Related]  

  • 5. Topical calcineurin inhibitors for the treatment of vulvar dermatoses.
    Goldstein AT; Thaçi D; Luger T
    Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):22-9. PubMed ID: 19631446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.
    Schneeweiss S; Doherty M; Zhu S; Funch D; Schlienger RG; Fernandez-Vidaurre C; Seeger JD
    Dermatology; 2009; 219(1):7-21. PubMed ID: 19293564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of Darier's disease with topical pimecrolimus.
    Pérez-Carmona L; Fleta-Asín B; Moreno-García-Del-Real C; Jaén-Olasolo P
    Eur J Dermatol; 2011; 21(2):301-2. PubMed ID: 21489907
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of topical calcineurin inhibitors in lupus erythematosus: an overview.
    Wollina U; Hansel G
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):1-6. PubMed ID: 18005117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion.
    Hartmann A; Bröcker EB; Hamm H
    J Dtsch Dermatol Ges; 2008 May; 6(5):383-5. PubMed ID: 18042249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis.
    Ingram JR; Martin JA; Finlay AY
    Am J Clin Dermatol; 2009; 10(4):229-37. PubMed ID: 19489656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical pimecrolimus 1% for the treatment of pruritic external auditory canals.
    Djalilian HR; Memar O
    Laryngoscope; 2006 Oct; 116(10):1809-12. PubMed ID: 17003726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison.
    Draelos Z; Nayak A; Pariser D; Shupack JL; Chon K; Abrams B; Paul CF
    J Am Acad Dermatol; 2005 Oct; 53(4):602-9. PubMed ID: 16198779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption.
    Chu CY
    J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):484-90. PubMed ID: 17373975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study.
    Jacobi A; Braeutigam M; Mahler V; Schultz E; Hertl M
    Dermatology; 2008; 216(2):133-6. PubMed ID: 18216475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pimecrolimus: skin disposition after topical administration in minipigs in vivo and in human skin in vitro.
    Gschwind HP; Waldmeier F; Zollinger M; Schweitzer A; Grassberger M
    Eur J Pharm Sci; 2008 Jan; 33(1):9-19. PubMed ID: 17996430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Selective calcineurin inhibitor. Neurodermatitis patients need fewer corticoids].
    MMW Fortschr Med; 2002 Nov; 144(46):70. PubMed ID: 12534090
    [No Abstract]   [Full Text] [Related]  

  • 17. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application.
    Weiss HM; Fresneau M; Moenius T; Stuetz A; Billich A
    Drug Metab Dispos; 2008 Sep; 36(9):1812-8. PubMed ID: 18524871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Local treatment of atopic dermatitis with calcineurin inhibitors].
    Langeland T
    Tidsskr Nor Laegeforen; 2006 Jan; 126(3):321-2. PubMed ID: 16440040
    [No Abstract]   [Full Text] [Related]  

  • 19. [Topical calcineurin inhibitors in atopic eczema -- pro].
    Wollenberg A
    Dtsch Med Wochenschr; 2006 Jul; 131(28-29):1614. PubMed ID: 16823713
    [No Abstract]   [Full Text] [Related]  

  • 20. Topical pimecrolimus in the treatment of vitiligo.
    Boone B; Ongenae K; Van Geel N; Vernijns S; De Keyser S; Naeyaert JM
    Eur J Dermatol; 2007; 17(1):55-61. PubMed ID: 17324829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.